According to the latest report by IMARC Group, titled “Intravenous (IV) Ibuprofen Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028,” the global intravenous (IV) ibuprofen market size reached US$ 6.3 Billion in 2022. Intravenous (IV) ibuprofen is a pharmaceutical formulation of the well-known nonsteroidal anti-inflammatory drug (NSAID) Ibuprofen, administered intravenously rather than orally. It is primarily used for the management of pain and reduction of inflammation in patients unable to take oral medications due to various medical conditions or surgical procedures. The IV Ibuprofen is typically indicated for short-term treatment and is not intended for chronic use. The intravenous route of administration allows for rapid absorption of the drug into the bloodstream, leading to faster onset of action compared to oral Ibuprofen. This makes it particularly useful in post-operative settings, where timely pain relief is crucial for patient comfort and recovery. As with any medication, IV Ibuprofen carries potential side effects and should be used under the supervision of qualified healthcare professionals. Common adverse reactions may include gastrointestinal disturbances, such as nausea, vomiting, and gastric irritation. It is essential for healthcare providers to consider the patient's medical history, concurrent medications, and allergies before prescribing IV Ibuprofen to mitigate the risk of any complications.
Global Intravenous (IV) Ibuprofen Market Trends:
The increasing number of surgical procedures, both elective and non-elective, is propelling the demand for effective post-operative pain management solutions, which represents one of the key factors driving the growth of the market across the globe. IV Ibuprofen, with its fast-acting pain relief capabilities, is becoming a preferred choice for managing pain in surgical settings, which is driving its market growth. The market is also driven by the growing aging population, which is leading to a rise in the prevalence of chronic pain conditions, joint-related issues, and age-related surgeries. IV Ibuprofen provides a viable solution for pain management in elderly patients who face difficulty taking oral medications, thus making it a significant driver of the market. IV Ibuprofen's pharmacokinetic advantages, such as faster absorption and higher bioavailability as compared to oral formulations, are making it an attractive option for healthcare providers. The convenience and effectiveness of the intravenous route are fostering its adoption in various medical facilities. The opioid epidemic and concerns over the potential for addiction are rising the search for non-opioid alternatives for pain management. IV Ibuprofen, being a non-opioid analgesic, is gathering attention as a safer option for pain relief, which is driving its market growth. As more clinical data support the efficacy and safety of IV Ibuprofen, healthcare institutions are increasingly adding it to their formulary. Inclusion in hospital formularies enhances accessibility and adoption of IV Ibuprofen in patient care, which is creating a positive outlook for the market across the globe. Looking forward, the market value is projected to reach US$ 10.2 Billion by 2028, expanding at a CAGR of 7.78% during 2023-2028.
- Based on the product dose, the market has been segmented into 100 Mg dose, 200 Mg dose, 400 Mg dose, and 800 Mg dose.
- On the basis of the indication, the market has been bifurcated into pain/inflammatory and fever. Presently, pain/inflammatory holds the largest market share across the globe.
- Based on the basis of the age group, the market has been divided into pediatrics and adults. Currently, adults dominate the market across the globe.
- Based on the region, the market has been divided into North America (United States and Canada), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, United Kingdom, Italy, Spain, Russia, and others), Latin America (Brazil, Mexico, and others), and the Middle East and Africa. Presently, North America holds the largest market share across the globe.
- The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market. Some of the key players include Cumberland Pharmaceuticals Inc., Hyloris Pharmaceuticals SA, Recordati Rare Diseases Inc., VALMOR Laboratories CA, and Xgen Pharmaceuticals Djb Inc.
|Base Year of the Analysis
||Product Dose, Indication, Age Group, Region
|| Asia Pacific, Europe, North America, Latin America, Middle East and Africa
||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
||Cumberland Pharmaceuticals Inc., Hyloris Pharmaceuticals SA, Recordati Rare Diseases Inc., VALMOR Laboratories CA and Xgen Pharmaceuticals Djb Inc.
||10% Free Customization
|Report Price and Purchase Option
||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support
||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
134 N 4th St.
Brooklyn, NY 11249, USA
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800